Skip to main content
main-content

Lung and thoracic cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

Detection bias may contribute to reduced prostate cancer risk in diabetes

PSA test

The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.

medwireNews top story

Different ADT combination therapies offer similar prostate cancer survival benefits

Prostate cancer medicines

Adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to androgen deprivation therapy significantly improves survival for men with metastatic hormone-sensitive prostate cancer, with little difference between each drug, a network meta-analysis shows.

medwireNews top story

Network meta-analysis identifies best clinical choices for EGFR-mutated NSCLC

Pills_syringe

Osimertinib and gefitinib plus pemetrexed-based chemotherapy offer the best survival outcomes for patients with advanced EGFR-mutated non-small-cell lung cancer compared with other first-line treatments, shows a network meta-analysis of randomized trials.

medwireNews top story

STELLAR shows potential of tumor treating fields in mesothelioma

Lungs_illustration

Combining tumor treating fields with standard chemotherapy could be a promising option for the first-line treatment of inoperable malignant pleural mesothelioma, say the STELLAR investigators.

medwireNews top story

PROfound paves the way for precision medicine in mCRPC

DNA mutation

Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.

Expert opinion

Current therapies for advanced NSCLC: The role of maintenance therapy in an immunotherapy world

Immunotherapy/maintenance therapy

Thomas Stinchcombe (Duke Cancer Institute, USA) examines the development of maintenance regimens and where they fit as immunotherapy continues to change treatment paradigms for NSCLC.

Content collection

Brain metastases in NSCLC

Brain MRI

A content collection providing HCPs with education around the burden, diagnosis and treatment of brain metastases arising from NSCLC.

Made possible by independent educational funding provided by AstraZeneca.

IASLC 2019 World Conference on Lung Cancer: Independent satellite symposium

Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations

Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations

Chaired by Corey Langer with Enriqueta Felip, David Heigener and Myung-Ju Ahn
Access the scientific summary with video highlights and faculty interviews, including take-home messages from the symposium.

medwireNews top story

Notable number of patients taking immune checkpoint inhibitors hospitalized with irAEs

Doctor_hospital bed

Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.

04-10-2019 | Non-small-cell lung cancer | Video | Article

Expert comment: The CheckMate 227 study

Sanjay Popat brings context to the CheckMate 227 data in light of the currently available options for patients with treatment-naïve, advanced non-small-cell lung cancer, highlighting the key aspects physicians need to bear in mind when considering nivolumab­ plus ipilimumab for their patients (2:20).

03-10-2019 | Non-small-cell lung cancer | Video | Article

Expert comment: Brain metastases in lung cancer

Lizza Hendriks provides insight into two studies focusing on brain metastases in patients with non-small-cell lung cancer, the ASCEND-7 trial of ceritinib and an analysis of the genomic and epigenomic landscape of the metastases (4:26).

02-10-2019 | Non-small-cell lung cancer | Video | Article

Expert highlights: Lung and thoracic cancers at ESMO 2019

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

01-10-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Take-home messages from the CheckMate 227 trial

Solange Peters discusses the implications of the CheckMate 227 findings for the front-line treatment of advanced non-small-cell lung cancer and outlines the key next steps (3:45).

01-10-2019 | Mesothelioma | Video | Article

Researcher comment: PROMISE-meso trial fails to meet primary endpoint

Sanjay Popat reports on the trial pitting pembrolizumab against chemotherapy in relapsed malignant pleural mesothelioma and outlines possible strategies for taking immune checkpoint inhibitors forward (4:53). 

29-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Positive OS data for osimertinib in FLAURA trial

Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).

09-10-2019 | Non-small-cell lung cancer | Editorial | Article

Current therapies for advanced NSCLC: The role of maintenance therapy in an immunotherapy world

Thomas Stinchcombe (Duke Cancer Institute, USA) examines the development of maintenance regimens and where they fit as immunotherapy continues to change treatment paradigms for NSCLC.

23-09-2019 | Non-small-cell lung cancer | WCLC 2019 | Article

Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’

LISTEN | Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation –  in patients with locally advanced or metastatic non-small-cell lung cancer (3:40).

28-01-2019 | Immunotherapy | Podcast | Audio

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

Reference

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

08-08-2017 | Non-small-cell lung cancer | At a glance | Article

At a glance: The KEYNOTE lung cancer trials

Here is our updated quick-access guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in the non-small-cell and small-cell lung cancer settings.

Updated July 2019

01-02-2017 | Immunotherapy | Primer | Collection

The fundamentals of cancer immunotherapy

A introductory guide to cancer immunotherapy for non-specialists, focusing primarily on the mechanisms of immune checkpoint inhibition and the role of these agents in anticancer therapy.

Journal articles and book chapters

Our Editorial Board advisor

Fiona Blackhall

Dr Blackhall is a Professor of Thoracic Oncology with expertise in personalized medicine and circulating biomarkers within the Institute of Cancer Studies, University of Manchester and has been a Consultant Medical Oncologist at The Christie Hospital, Manchester since 2005. She has conducted over 50 therapeutic clinical trials, including practice-changing precision medicine studies, and led on new directions in radiotherapy-related research and supportive palliative care research.

Image Credits